

# Beyond the Lab: Scaling Wearables for Real-World Impact through Partnerships and Implementation

Studzinski, CM<sup>1</sup>; Siu, C<sup>1</sup>; Spring, R<sup>2</sup>; Jelen, A<sup>2</sup>; Porter, N<sup>3</sup>; Bornbaum, C<sup>4</sup>; Tsotsos, LE<sup>5</sup>; Morrison, A<sup>6</sup>; Stergiou-Dayment, C<sup>6</sup>

<sup>1</sup>Ontario Brain Institute; <sup>2</sup>Translational Research Program, University of Toronto; <sup>3</sup>Epilepy Ottawa; <sup>4</sup>RetiSpec Inc.; <sup>5</sup>Centre for Elder Research, Sheridan College; <sup>6</sup>Alzheimer Society of Ontario

#### ABSTRACT:

Despite the advancement of wearable technologies, widespread adoption and implementation of these potentially transformative technologies to support aging individuals, including those with mild cognitive impairment (MCI), Alzheimer's disease, and related dementias (ADRD), has yet to be achieved. This barrier to adoption has prevented us from fully realizing the potential transformative impact wearables could have – both in the delivery of compassionate and accessible dementia care and in improving outcomes for aging individuals. This session will share lessons learned from the Ontario Brain Institute's journey to co-design and launch a program called CORTEX (Community-led Real-world neuroTech EXperience) that empowers community groups and people with lived experience in testing, implementing, and scaling wearable technology.

Here we share how the initial concept for CORTEX emerged, how the program was initially codesigned with community groups and people with lived experience, and the learnings from the first pilots conducted in partnership with patient groups. Finally, we will show how the learnings informed the launch of our flagship CORTEX initiative, the Canadian Dementia Registry, which was co-created in partnership with the Alzheimer Society of Ontario. This registry allows us to (1) understand the earliest stage of the dementia journey diagnosis (including how conducting cognitive assessments in the community, on behalf of primary care practitioners fills an early detection gap), (2) test neurotechnologies in diverse populations and compare them to clinicallyrelevant scales (e.g., Montreal Cognitive Assessment), and (3) look at how these technologies can fit into the care pathway in local communities so that we can increase access to the right clinicians and care they need and deserve.

#### **Ontario Brain Institute**


The Ontario Brain Institute is advancing brain health solutions into communities across Ontario

and Canada. POND NETWORK
Province of Ontario Neurodevelopmental Disorders


Calm **NERVE and NERD** CP-NET CAN-BIND Neurotech funding programs TRANSCENDENT Clinical validation studies >100 Portfolio >20 Clinical + companies Strategic clinica across the brain health **CORTEX** ONTARIO INSTITUT BRAIN ONTARIEN Community-led testing Standardized INSTITUTE DU CERVEAU clinical data >29K human records Brain-CODE Real-world data Informatics + >40 Community partners + (e.g., digital health) **Evaluation** capacity **Centre for Analytics** Patient groups in the community

#### 2. What is CORTEX?

Community-led Real-world neuroTech EXperience (CORTEX) is an Ontario Brain Institute program for implementing and evaluating neurotech in the community.



To date, 10 partnerships engaged 1433 individuals



**IDEA: Why CORTEX?** 

Companies and community WANT to work together


# Neurotech

- Personal Connection
- Want end user feedback
- Need help with adoption in home market

## Community ( mining )

- Want to co-design
- Want to use neurotech
- Know their condition best

#### **REPORT: Health Innovation** Implementation in Ontario



### Importance of Real-World Data

The FDA Is Opening the Use of Registry Data in Drug Development – What Does It Mean for Patient Advocacy Groups?

https://medcitynews.com/2022/12/the-fda-is-opening-the-use-ofegistry-data-in-drug-development-what-does-it-mean-for-patient <u>advocacy-groups/</u>


#### **CO-CREATE:** Could we partner to test neurotech?

- Ontario Brain Institute hosts an annual patient and community advisory group day for our lived experience partners. Typically, between 40-60 individuals attend.
- In 2020, we held a session to determine interest in testing neurotech, in partnership with the Ontario Brain Institute.

#### **KEY FINDINGS:**

- 98% of attendees were interested in testing neurotech with the Ontario **Brain Institute**
- 2. The program needs to consider the following topics:

#### **MUST BE IMPACTFUL!**



COST Affordability One time vs subscription

Who pays

### **ACCESSIBILITY**

Ease of use Universal design Thresholds of need

**Thank you to our funders!** Government of Ontario, Ontario Brain Institute, Canadian Institutes for Health Research, Davos Alzheimer's Collaborative, Eisai Canada, Eli Lilly Canada, Novo Nordisk Canada, envisAGE.

## **PILOT: Partner and test with community**

Wearable + App for tracking seizures, medication and sleep (n=50)

Holland Bloorview Wearable + App for predicting emotional outbursts in neurodiverse children (n=125)

Concussion recovery app (n=103)

RetiSpe**c Alzheimer** 

Retinal scan for detecting Alzheimer's in the optometry clinic (n=916)

Elder Research

Digital human + speech algorithms for monitoring cognitive decline and mental health (n=60)



#### **LEARN**: Lessons learned from pilots

Build capacity in the community – research, data collection, neurotech selection

Sustainability – capacity is lost after project ends

Implementation – create and test alternate care pathways

## **EVOLVE: Canadian Dementia Registry**

#### **Alzheimer** Society ONTARIO

**STANDARDIZED** 

**DATA ELEMENTS** Demographics Cognitive Scores

**Functional Assessment** 

#### **NEUROTECH+ PROGRAMS**

Digital Cognitive Assessments Sleep Intervention Minds in Motion Caregiver support

## ONTARIO INSTITUT BRAIN ONTARIEN INSTITUTE DU CERVEAU **BRAIN-CODE** Informatics platform Data quality framework Centre for Analytics

### **UNBIASED VALIDATOR**

Centre for Analytics Real-world validation Implementation and Evaluation

# **IMPACT**

**REAL-WORLD EVIDENCE** 

**DE-RISK AND SCALE SOLUTIONS** 

**IMPROVE DEMENTIA CARE** 

MEET PEOPLE WHERE THEY ARE

Started with 3 community sites.

- Leveraging a successful program for conducting cognitive and functional assessments on behalf of primary care to support detection of Alzheimer's Disease and Related Dementias.
- First technology: Digital Cognitive Assessment to identify individuals that should be prioritized for cognitive assessments.

Want to learn more? We're happy to answer questions and explore partnerships! Christa Studzinski: cstudzinski@braininstitute.ca Caitlin Siu: csiu@braininstitute.ca